Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Acta Pharm ; 69(3): 297-319, 2019 Sep 01.
Artículo en Inglés | MEDLINE | ID: mdl-31259738

RESUMEN

The original purpose of vaginally applied microbicides was to slow down the HIV epidemic among the population until an effective vaccination was developed. Nowadays, antiretrovirals applied in the form of gels or vaginal rings are considered most prominent in this field and are tested via vaginal or, rarely, rectal applications in numerous clinical studies (9 different antiretroviral drugs in 33 clinical studies, especially in Africa). Only tenofovir (1 % gel) and dapivirine (25 mg in vaginal ring) progressed into the phase III clinical testing. Their efficiency depended on the user´s strict adherence to the application regimen (for tenofovir 54 %, for dapivirine 61 % in participants over 25 years of age). Despite this, they are expected to be important and effective tools of preventive medicine in the near future. This review summarizes the results obtained during long-term clinical testing (2005-2018) of antiretroviral drugs against vaginal and rectal transmission of HIV infection.


Asunto(s)
Antirretrovirales/uso terapéutico , Dispositivos Anticonceptivos Femeninos/virología , Infecciones por VIH/tratamiento farmacológico , Recto/virología , Vagina/virología , Ensayos Clínicos Fase III como Asunto , Femenino , Humanos
2.
J Control Release ; 213: 57-68, 2015 Sep 10.
Artículo en Inglés | MEDLINE | ID: mdl-26091920

RESUMEN

Women urgently need a self-initiated, multipurpose prevention technology (MPT) that simultaneously reduces their risk of acquiring HIV-1, HSV-2, and HPV (latter two associated with increased risk of HIV-1 acquisition) and prevents unintended pregnancy. Here, we describe a novel core-matrix intravaginal ring (IVR), the MZCL IVR, which effectively delivered the MZC combination microbicide and a contraceptive. The MZCL IVR contains four active pharmaceutical ingredients (APIs): MIV-150 (targets HIV-1), zinc acetate (ZA; targets HIV-1 and HSV-2), carrageenan (CG; targets HPV and HSV-2), and levonorgestrel (LNG; targets unintended pregnancy). The elastomeric IVR body (matrix) was produced by hot melt extrusion of the non-water swellable elastomer, ethylene vinyl acetate (EVA-28), containing the hydrophobic small molecules, MIV-150 and LNG. The solid hydrophilic core, embedded within the IVR by compression, contained the small molecule ZA and the macromolecule CG. Hydrated ZA/CG from the core was released by diffusion via a pore on the IVR while the MIV-150/LNG diffused from the matrix continuously for 94 days (d) in vitro and up to 28 d (study period) in macaques. The APIs released in vitro and in vivo were active against HIV-1ADA-M, HSV-2, and HPV16 PsV in cell-based assays. Serum LNG was at levels associated with local contraceptive effects. The results demonstrate proof-of-concept of a novel core-matrix IVR for sustained and simultaneous delivery of diverse molecules for the prevention of HIV, HSV-2 and HPV acquisition, as well as unintended pregnancy.


Asunto(s)
Antivirales/administración & dosificación , Dispositivos Anticonceptivos Femeninos/virología , Sistemas de Liberación de Medicamentos/instrumentación , Infecciones por VIH/prevención & control , Herpes Genital/prevención & control , Levonorgestrel/administración & dosificación , Infecciones por Papillomavirus/prevención & control , Administración Intravaginal , Animales , Antivirales/farmacocinética , Antivirales/farmacología , Carragenina/administración & dosificación , Carragenina/farmacocinética , Carragenina/farmacología , Línea Celular , Anticonceptivos Femeninos/administración & dosificación , Anticonceptivos Femeninos/farmacocinética , Anticonceptivos Femeninos/farmacología , Diseño de Equipo , Femenino , Transcriptasa Inversa del VIH/antagonistas & inhibidores , VIH-1/efectos de los fármacos , Células HeLa , Herpesvirus Humano 2/efectos de los fármacos , Papillomavirus Humano 16/efectos de los fármacos , Humanos , Levonorgestrel/farmacocinética , Levonorgestrel/farmacología , Macaca mulatta , Embarazo , Piridinas/administración & dosificación , Piridinas/farmacocinética , Piridinas/farmacología , Urea/administración & dosificación , Urea/análogos & derivados , Urea/farmacocinética , Urea/farmacología , Acetato de Zinc/administración & dosificación , Acetato de Zinc/farmacocinética , Acetato de Zinc/farmacología
3.
Antiviral Res ; 88 Suppl 1: S30-9, 2010 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-21109066

RESUMEN

Vaginal ring devices capable of providing sustained/controlled release of incorporated actives are already marketed for steroidal contraception and estrogen replacement therapy. In recent years, there has been considerable interest in developing similar ring devices for the administration of microbicidal compounds to prevent vaginal HIV transmission. Intended to be worn continuously, such coitally independent microbicide rings are being developed to maintain effective vaginal microbicide concentrations over many weeks or months, thereby overcoming issues around timing of product application, user compliance and acceptability associated with more conventional semi-solid formulations. In this article, an overview of vaginal ring technologies is presented, followed by a review of recent advances and issues pertaining to their application for the delivery of HIV microbicides. This article forms part of a special supplement on presentations covering intravaginal rings, based on the symposium "Trends in Microbicide Formulations", held on 25 and 26 January 2010, Arlington, VA.


Asunto(s)
Fármacos Anti-VIH/administración & dosificación , Antiinfecciosos/administración & dosificación , Materiales Biocompatibles Revestidos/química , Materiales Biocompatibles Revestidos/uso terapéutico , Dispositivos Anticonceptivos Femeninos/economía , Dispositivos Anticonceptivos Femeninos/normas , Dispositivos Anticonceptivos Femeninos/virología , Infecciones por VIH/prevención & control , VIH/efectos de los fármacos , Administración Intravaginal , Fármacos Anti-VIH/química , Fármacos Anti-VIH/uso terapéutico , Antiinfecciosos/química , Antiinfecciosos/uso terapéutico , Química Farmacéutica , Materiales Biocompatibles Revestidos/normas , Costos y Análisis de Costo , Formas de Dosificación , Control de Medicamentos y Narcóticos , Femenino , Infecciones por VIH/tratamiento farmacológico , Infecciones por VIH/transmisión , Humanos , Masculino , Factores de Riesgo , Vagina/efectos de los fármacos , Vagina/virología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA